18% of Indian pharma launches to be delayed in US, says Crisil

The warning letter issued by USFDA to large pharma companies more than doubled in the first 10 months of 2019 compared with the previous year, CRISIL said, adding that close to 180 generic drug launches will be pushed out from their intended launch dates due to it.